Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS - Wikidata - wikimedia - TriplyDB

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

http://www.wikidata.org/entity/Q28268439

about

Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole Treatment of infection due to Pneumocystis carinii Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations Pneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future Directions Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites Antipneumocystis activity of 17C91, a prodrug of atovaquone Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia Characterization of nebulized buparvaquone nanosuspensions--effect of nebulization technology.Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.Prevention of adverse events in hospitalized patients using an antimicrobial review program.Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team HIV: treating Pneumocystis pneumonia (PCP)Antiparasitic agent atovaquone Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Medicaid policies for HIV-related prescription drugs.Prevention of infection caused by Pneumocystis carinii in transplant recipients.Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions.Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals.Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia.Antimalarial pharmacology and therapeutics of atovaquone Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia.Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions.Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal."Human babesiosis": an emerging transfusion dilemma Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.AIDS and the lung: update 1995. 1. Pneumocystis carinii pneumonia Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia.Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.

P2860

Q24245223-F9BEE6CF-53B2-45F3-BE13-2C7F46F6EB29 Q24245408-21A46467-ACBE-4630-9C03-5917A0707DBB Q24519016-2CF81D84-AC07-4F1A-B4C9-5914105FC784 Q26781920-5363F790-DAE9-4CAF-81DF-9F71DF7EE1FA Q26795592-1167961D-D330-4925-876F-ADB63D6BB6EA Q28365205-EBC6CBCE-7955-4F48-8A6B-EEEA717943C9 Q28368064-DFC3F4E9-6A4E-4AF8-A166-5E10C91EAA08 Q28368166-E2CE138F-564F-4E6C-BE52-D68AE5C91CB0 Q28370808-0C52FEE6-EDAC-43C9-8463-D4CA4F9405F9 Q28378822-EC63B53B-68E6-4475-908A-516F836CCE85 Q28379209-336FF4EC-8633-42E9-8CE9-1DB155190A61 Q33228693-97C83F00-6FDA-4EB1-802D-DD8919F846E9 Q33693150-1DAB5272-293D-4DAE-8B18-41B236D21E2B Q33772759-542D0DDA-3834-46DF-A768-6D9BDD3C2D32 Q33977020-3C818E5B-A00D-4B10-9A42-85C5D1354899 Q34011311-06EF2E80-770C-4BFF-9172-5B975D8840C9 Q34107885-116A1819-C4EA-4A43-9DAB-71E437D7976B Q34212799-4514FDB5-F7C9-42D1-9DE4-7C80A6A120EC Q34321740-F1016382-9B17-421E-9EC3-88F681276AB9 Q34374874-2D630FDB-BB23-4F5F-BF79-9981DCAA82B4 Q34446538-79FF8087-D065-42F6-806C-CDA6746884CC Q34718247-475DB2D2-58A4-4A47-90F5-AA0EC0AC2F63 Q35120725-51828916-B7C4-41A3-89F8-E9D583F44448 Q35131253-93459752-8422-4DAC-91F0-3258602AC510 Q35191258-ACC6358A-1D1B-40FF-ACBE-E226268B87C5 Q35557252-4BDF2CCE-1C1A-43E2-98FF-FE68CC8DADB7 Q35557331-2C944159-726A-4AE1-91CE-125F3B4D7AF9 Q35875187-008F68ED-DE0B-4D10-80B4-DA756D9FB0C7 Q35897483-7623A798-B1A2-40B2-BC39-1A11A4199097 Q35920640-A1D229D9-031A-4303-86AA-75088D66AB01 Q36538285-054EBE37-43C8-4940-8F5B-247DBCDB0BB3 Q36644639-3E2DB5D5-97DC-4138-A687-3B65EF2B32EB Q36715824-85C511D9-38CD-4E08-8DBF-AFADF1C8C41D Q36958088-93B36C99-9F58-4043-9693-0C553E1720CD Q37150434-5DB774A8-16EC-4D4F-8AB9-FDAB7FACC6C9 Q37180338-2B6B21A8-8BCD-472B-80F3-9F6B7BE4367A Q37376205-2FC4BB75-E0F3-4793-8841-33E48D89546E Q37634515-DA3E392C-FD54-402B-A718-6695AA56ED87 Q38284466-7B9626DB-2941-43E6-B23E-EDC64C099A02 Q38848880-6B1034AD-70D7-43B1-B732-38B6C034CD69

P2860

Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS

http://www.wikidata.org/entity/Q28268439

description

1993 nî lūn-bûn

@nan

1993 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@ast

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@en

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@nl

type

label

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@ast

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@en

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@nl

prefLabel

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@ast

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@en

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@nl

P1433

Q28268439-E9C95C89-99CF-4FAD-A124-82CC8FB355EF

P1476

Q28268439-F6AB4680-B704-4290-99AA-0D1A9AFBFFAC

P2093

Q28268439-0A67643F-CEF1-4C6A-876F-C01A45741950

Q28268439-0E578070-4274-499D-B0BA-A7BEE9BDD25D

Q28268439-34EFAE73-FC2B-4B61-8C7A-513B8D66EB8D

Q28268439-3AA8C71B-AD34-436B-9FF7-FBFD72CF8433

Q28268439-43D5B48C-B04C-403A-B0D5-06C5E3D979B8

Q28268439-5117B701-A452-4D4B-8758-DF4AE2103CD6

Q28268439-5705223D-E62F-4F1F-8A69-4C7DAF69A144

Q28268439-64905359-B210-4EBA-BF41-80B175EA1075

Q28268439-80395EA7-D4F9-4F39-94F5-A0827A955C9D

Q28268439-E187F95E-574B-4398-BE48-7D42E3272DF3

P304

Q28268439-A3094DFB-7F85-4C05-B926-1C3B0188D3DC

P31

Q28268439-0B969A09-C4A7-46A2-996D-6C2DC149CF1C

P3181

Q28268439-70F9CC67-3BB5-4A0F-B1F2-89DC3AB2239D

P356

Q28268439-FFC90961-4B9F-4051-B6D9-D56F25D41C55

P407

Q28268439-BD101E8E-90EB-43DB-A87E-CECFA7F09068

P433

Q28268439-6C72F33F-70A6-41C8-A689-87D5F2982BC2

P478

Q28268439-BADD3836-9C2C-465D-84CA-F371A52BBE94

P577

Q28268439-7003A75D-C51A-4C85-AA8A-A610F539AFDA

P698

Q28268439-3E65F93A-03C9-4FE9-A757-E5300AAE75E0

P921

Q28268439-1B8A2B65-1C0B-44FE-ADA3-630BD99661EF

Q28268439-27D94E14-984F-464F-BFEE-92A1CAD0A34F

Q28268439-F29087AC-5768-4F79-926E-6AE153910B41

P3181

P356

NEJM199305273282103

P1433

The New England Journal of Medicine

P1476

Comparison of atovaquone (566C ...... neumonia in patients with AIDS

@en

P2093

C Chan

http://www.w3.org/2001/XMLSchema#string

D Lancaster

http://www.w3.org/2001/XMLSchema#string

F Kramer

http://www.w3.org/2001/XMLSchema#string

G Leoung

http://www.w3.org/2001/XMLSchema#string

H Masur

http://www.w3.org/2001/XMLSchema#string

N Clumeck

http://www.w3.org/2001/XMLSchema#string

P Frame

http://www.w3.org/2001/XMLSchema#string

S A Bozzette

http://www.w3.org/2001/XMLSchema#string

S Safrin

http://www.w3.org/2001/XMLSchema#string

W Hughes

http://www.w3.org/2001/XMLSchema#string

P304

1521-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1304967

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199305273282103

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

328

http://www.w3.org/2001/XMLSchema#string

P577

1993-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8479489

http://www.w3.org/2001/XMLSchema#string

P921